Labcorp Holdings Inc. (LH) Debt to Equity Ratio: 0.84
Is Labcorp Holdings Inc.’s debt to equity ratio high or low?
Labcorp Holdings Inc.'s debt to equity ratio of 0.84 is 13% above its 5-year average of 0.74, near the high end of its 5-year range (0.62–0.90).
As of Sunday, June 14, 2026. 3.45% below its 12-month average of 0.87.
LH Debt to Equity Ratio Chart
LH Average Debt to Equity Ratio Chart
LH Current vs Average Debt to Equity Ratio Chart
LH Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.84
DEBT TO EQUITY RATIO AVG TTM
0.87
DEBT TO EQUITY RATIO AVG 3Y
0.78
DEBT TO EQUITY RATIO AVG 5Y
0.74
DEBT TO EQUITY RATIO AVG 10Y
0.87
DEBT TO EQUITY RATIO AVG 15Y
0.91
DEBT TO EQUITY RATIO AVG 20Y
0.88
CURRENT VS TTM AVG
-3.45%
CURRENT VS 3Y AVG
+7.69%
CURRENT VS 5Y AVG
+13.00%
CURRENT VS 10Y AVG
-3.85%
CURRENT VS 15Y AVG
-8.20%
CURRENT VS 20Y AVG
-4.60%
LH Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Labcorp Holdings Inc. (LH) | $21.83B | 0.84 | 0.87 | 0.78 | 0.74 |
| Mettler-Toledo International Inc. (MTD) | $22.86B | -99.14 | 48.23 | 26.06 | 17.96 |
| BioNTech SE (BNTX) | $22.90B | 0.01 | 0.01 | 0.01 | 0.04 |
| United Therapeutics Corporation (UTHR) | $23.17B | 0.00 | 0.03 | 0.09 | 0.13 |
| Waters Corporation (WAT) | $23.17B | 0.58 | 0.76 | 1.73 | 2.93 |
| Moderna, Inc. (MRNA) | $19.80B | 0.22 | 0.15 | 0.11 | 0.10 |
| Veeva Systems Inc. (VEEV) | $25.92B | 0.01 | 0.01 | 0.01 | 0.02 |
| Hologic, Inc. (HOLX) | $16.97B | 0.52 | 0.52 | 0.55 | 0.69 |
| DexCom, Inc. (DXCM) | $29.08B | 0.51 | 0.87 | 1.00 | 1.01 |
| Biogen Inc. (BIIB) | $29.53B | 0.38 | 0.39 | 0.44 | 0.53 |
Financial Health
Debt/Equity
0.84
Current Ratio
1.42
Labcorp Holdings Inc. Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Labcorp Holdings Inc. Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Labcorp Holdings Inc. (LH)?
- The debt to equity ratio for LH stock is 0.84.
- Is Labcorp Holdings Inc.'s debt to equity ratio high or low?
- Labcorp Holdings Inc.'s debt to equity ratio of 0.84 is 13% above its 5-year average of 0.74, near the high end of its 5-year range (0.62–0.90).
- What is the TTM average debt to equity ratio for Labcorp Holdings Inc. (LH)?
- The TTM average debt to equity ratio for LH stock is 0.87.
- What is the 3Y average debt to equity ratio for Labcorp Holdings Inc. (LH)?
- The 3Y average debt to equity ratio for LH stock is 0.78.
- What is the 5Y average debt to equity ratio for Labcorp Holdings Inc. (LH)?
- The 5Y average debt to equity ratio for LH stock is 0.74.
- What is the 10Y average debt to equity ratio for Labcorp Holdings Inc. (LH)?
- The 10Y average debt to equity ratio for LH stock is 0.87.
- What is the 15Y average debt to equity ratio for Labcorp Holdings Inc. (LH)?
- The 15Y average debt to equity ratio for LH stock is 0.91.
- What is the 20Y average debt to equity ratio for Labcorp Holdings Inc. (LH)?
- The 20Y average debt to equity ratio for LH stock is 0.88.
Labcorp Holdings Inc. Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.84 |
| 2024-12-31 | 0.90 |
| 2023-12-31 | 0.76 |
| 2022-12-31 | 0.62 |
| 2021-12-31 | 0.62 |
| 2020-12-31 | 0.72 |
| 2019-12-31 | 0.94 |
| 2018-12-31 | 0.87 |
| 2017-12-31 | 0.99 |
| 2016-12-31 | 1.06 |
| 2015-12-31 | 1.29 |
| 2014-12-31 | 1.07 |
| 2013-12-31 | 1.20 |
| 2012-12-31 | 0.98 |
| 2011-12-31 | 0.89 |
| 2010-12-31 | 0.89 |
| 2009-12-31 | 0.66 |
| 2008-12-31 | 1.02 |
| 2007-12-31 | 0.97 |
| 2006-12-31 | 0.59 |
| 2005-12-31 | 0.61 |
| 2004-12-31 | 0.45 |
| 2003-12-31 | 0.47 |
| 2002-12-31 | 0.32 |
| 2001-12-31 | 0.47 |
| 2000-12-31 | 0.55 |
| 1999-12-31 | 0.79 |
| 1998-12-31 | 0.95 |
| 1997-12-31 | 1.09 |
| 1996-12-31 | 4.96 |
Related Metrics
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter